Akari Therapeutics Plc (NASDAQ: AKTX) is 16.00% higher on its value in year-to-date trading and has touched a low of $0.87 and a high of $3.35 in the current 52-week trading range. The AKTX stock was last observed hovering at around $2.03 in the last trading session, with the day’s loss setting it -0.03% off its average median price target of $5.00 for the next 12 months. It is also 60.0% off the consensus price target high of $5.00 offered by 1 analysts, but current levels are 60.0% higher than the price target low of $5.00 for the same period.
Currently trading at $2.00, the stock is -5.01% and -5.15% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.21 million and changing -1.48% at the moment leaves the stock 8.27% off its SMA200. AKTX registered 0.00% loss for a year compared to 6-month gain of 7.98%. The firm has a 50-day simple moving average (SMA 50) of $2.1708 and a 200-day simple moving average (SMA200) of $1.8503.
The stock witnessed a -2.40% loss in the last 1 month and extending the period to 3 months gives it a 25.31%, and is 2.01% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.44% over the week and 7.45% over the month.
Distance from 52-week low is 129.89% and -40.30% from its 52-week high.
Akari Therapeutics Plc (AKTX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Akari Therapeutics Plc (AKTX) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Akari Therapeutics Plc is expected to release its quarterly report on 09/24/2020 and quarterly earnings per share for the current quarter are estimated at $0.The EPS is expected to grow by 12.60% this year.
Akari Therapeutics Plc (AKTX) Top Institutional Holders
15 institutions hold shares in Akari Therapeutics Plc (AKTX), with 12.02M shares held by insiders accounting for 41.85% while institutional investors hold 5.56% of the company’s shares. The shares outstanding are 25.16M, and float is at 13.67M with Short Float at 0.60%. Institutions hold 3.23% of the Float.
The top institutional shareholder in the company is Hikari Power Ltd with over 1.5 million shares valued at $2.18 million. The investor’s holdings represent 9.46% of the AKTX Shares outstanding. As of Mar 30, 2020, the second largest holder is NEA Management Company, LLC with 0.45 million shares valued at $0.66 million to account for 2.85% of the shares outstanding. The other top investors are Omnia Family Wealth, LLC which holds 0.18 million shares representing 1.16% and valued at over $0.27 million, while Renaissance Technologies, LLC holds 0.82% of the shares totaling 0.13 million with a market value of $0.19 million.
Akari Therapeutics Plc (AKTX): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 52.32% up over the past 12 months. Short interest in the company’s stock has risen 65.05% from the last report on May 28, 2020 to stand at a total of 66720.0 short shares sold with a short interest ratio of 0.18.